Description

Intravenous Immunoglobulin (IVIG) is a therapy treatment for patients with antibody deficiencies. It is prepared from a pool of immunoglobulins (antibodies) from the plasma of thousands of healthy donors. Immunoglobulins are made by the immune system of healthy people for the purpose of fighting infections. According to StrategyHelix, the intravenous immunoglobulin market in United States is expected to increase by US$ 2.5 billion during 2022-2028, expanding at a CAGR of 6.4% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for intravenous immunoglobulin. The United States intravenous immunoglobulin market is segmented on the basis of application, and end user. Based on application, the intravenous immunoglobulin market in United States is categorized into chronic inflammatory demyelinating polyneuropathy (CIDP), chronic lymphocytic leukemia, congenital HIV/AIDS, guillain-barre syndrome (GBS), hypogammaglobulinemia, immune thrombocytopenic purpura (ITP), immunodeficiency diseases, kawasaki disease, multifocal motor neuropathy (MMN), myasthenia gravis, others. The immunodeficiency diseases segment held the largest share of the United States intravenous immunoglobulin market in 2021 and is anticipated to hold its share during the forecast period. On the basis of end user, the intravenous immunoglobulin market in United States has been segmented into homecare, hospitals & clinics.

The United States intravenous immunoglobulin market is highly competitive. Key companies profiled in the report include ADMA Biologics Inc., Biotest AG, CSL Limited, Grifols S.A., Johnson & Johnson, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Takeda Pharmaceutical Company Limited. Competitive landscape gives a description of the competitive nature of the intravenous immunoglobulin market in United States and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the intravenous immunoglobulin market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Application: chronic inflammatory demyelinating polyneuropathy (CIDP), chronic lymphocytic leukemia, congenital HIV/AIDS, guillain-barre syndrome (GBS), hypogammaglobulinemia, immune thrombocytopenic purpura (ITP), immunodeficiency diseases, kawasaki disease, multifocal motor neuropathy (MMN), myasthenia gravis, others
End user: homecare, hospitals & clinics
Years considered: this report covers the period 2018 to 2028
Company mentioned: ADMA Biologics Inc., Biotest AG, CSL Limited, Grifols S.A., Johnson & Johnson, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Takeda Pharmaceutical Company Limited

Key Benefits for Stakeholders

– Get a comprehensive picture of the United States intravenous immunoglobulin market
– Identify regional strategies and strategic priorities on the basis of local data
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Intravenous immunoglobulin market overview
Part 3. Market breakdown by application
– Chronic inflammatory demyelinating polyneuropathy (CIDP)
– Chronic lymphocytic leukemia
– Congenital HIV/AIDS
– Guillain-barre syndrome (GBS)
– Hypogammaglobulinemia
– Immune thrombocytopenic purpura (ITP)
– Immunodeficiency diseases
– Kawasaki disease
– Multifocal motor neuropathy (MMN)
– Myasthenia gravis
– Others
Part 4. Market breakdown by end user
– Homecare
– Hospitals & clinics
Part 5. Key companies
– ADMA Biologics Inc.
– Biotest AG
– CSL Limited
– Grifols, S.A.
– Johnson & Johnson
– Kedrion Biopharma Inc. (Kedrion SpA)
– LFB S.A.
– Octapharma AG
– Takeda Pharmaceutical Company Limited
About StrategyHelix
Disclaimer